Tonix Pharmaceuticals Licenses Technology for Treating Prader-Willi Syndrome, a Rare Genetic Eating Disorder, from the French National Institute of Health and Medical Research (Inserm) benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
Published: Jan 06, 2021
RAD011 is a pivotal-trial ready synthetic cannabidiol oral solution with potential utilization in multiple endocrine and metabolic orphan diseases
Prader-Willi syndrome (“PWS”) will be the initial indication, which has been granted Orphan Drug and Fast Track Designation by the FDA
Acquisition and associated PWS trial costs to be funded from existing operations
Management to host conference call and webcast this morning at 8:15 a.m. ET
BOSTON, Jan. 06, 2021 (GLOBE NEWSWIRE)
Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced a definitive agreement to acquire the global development and commercialization rights to
Benuvia Therapeutics Inc.’s (“Benuvia”) synthetic cannabidiol oral solution (“RAD011”). The Company plans to initiate a pivotal Phase 2/3 study for patients with Prader-Willi syndrome (“PWS”) in the second half of 2021 pending regulatory discussion with the U.S. Food and Drug Administr
Share this article
Share this article
PLYMOUTH MEETING, Pa. and CHICAGO, Dec. 15, 2020 /PRNewswire/ Harmony Biosciences Holdings, Inc. ( Harmony ) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced the first patient has been enrolled in a Phase 2 trial evaluating the safety and efficacy of pitolisant for the treatment of excessive daytime sleepiness (EDS) and other key symptoms in patients with Prader-Willi Syndrome (PWS). We view pitolisant as a portfolio in a product opportunity and are taking a mechanism-based approach to drug development in managing its life cycle with the goal of expanding its clinical utility, said Harmony s Chief Medical Officer, Jeffrey Dayno, M.D. We believe pitolisant could offer an important therapeutic benefit in people living with PWS based on preclinical models of the disorder, pitolisant s